Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
<p>At present, there are no compounds in clinical development in the field of chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) that have been documented to harbor significant activity against the imatinib-resistant T315I mutation. Recent reports on the...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2009-02-01
|
| Серія: | Hematology Reports |
| Предмети: | |
| Онлайн доступ: | http://www.pagepress.org/journals/index.php/hr/article/view/5 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|